10-K: Avalon GloboCare Corp. Files 10-K, Outlines Financials and Strategic Shifts

Sentiment:

Annual Report 31 March 2025 4:30 PM

Avalon GloboCare Corp. files its annual report on Form 10-K, detailing its financial performance, strategic shifts towards precision diagnostic consumer products, and a pending merger with YOOV Group Holding Limited.

Capital raiseThe company will need to raise additional capital or generate substantial revenue in order to support its development and commercialization efforts.The company may seek additional capital through a combination of private and public equity offerings, debt financings and strategic collaborations.The company is authorized to issue an aggregate of 100,000,000 shares of common stock and 10,000,000 shares of blank check preferred stock.

Worse than expectedThe company's net losses and working capital deficit have increased, raising substantial doubt about its ability to continue as a going concern.

Summary

Avalon GloboCare Corp. is focusing on precision diagnostic consumer products, particularly the Keto Air breathalyzer.
The company has ceased offering laboratory services to preserve cash.
A merger agreement with YOOV Group Holding Limited is expected to close in the third quarter of 2025.
The company incurred net losses of approximately $7.9 million in 2024 and $16.7 million in 2023.
As of December 31, 2024, the company had a working capital deficit of approximately $10.6 million.
The company is seeking additional capital through equity and debt offerings.
The company implemented a reverse stock split of 1-for-15 in October 2024.
The company is subject to various healthcare regulations and faces intense competition.
The company's auditor has raised substantial doubt about its ability to continue as a going concern.
The company is subject to the Foreign Corrupt Practices Act and other anti-corruption laws.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are strategic shifts and potential future opportunities, the financial results are poor, and the auditor has raised concerns about the company's ability to continue as a going concern. The pending merger adds uncertainty.

Positives

The company is focusing on a new area of business with precision diagnostic consumer products.
The company is seeking a strategic merger to improve its financial position.
The company owns commercial property that generates rental income.
The company has launched sales of the KetoAir in the U.S. in 2024.

Negatives

The company has a limited operating history and has not achieved profitability.
The company has a significant working capital deficit.
The company's auditor has raised substantial doubt about its ability to continue as a going concern.
The company is facing intense competition and is subject to various healthcare regulations.
The company has significant outstanding debt obligations.

Risks

Failure to complete the merger with YOOV could negatively impact the stock price and the company's future business.
The company's limited operating history makes it difficult to evaluate future business prospects.
The company's results of operations have not resulted in profitability and it may not be able to achieve profitability going forward.
The company's cash will only fund its operations for a limited time and it will need to raise additional capital in order to support its development.
The company faces intense competition which could cause it to lose market share.
The company may be exposed to liabilities under the Foreign Corrupt Practices Act.

Future Outlook

The company expects to complete its merger with YOOV Group Holding Limited in the third quarter of 2025, subject to customary closing conditions. The company expects that its revenue from real property rent will remain at its current level with minimal increase in the near future. The company expects that its professional fees will likely remain at their current level with minimal increase in the near future. The company expects that its compensation and related benefits will remain relatively steady, with minimal increase, in the near future. The company expects that its miscellaneous taxes will decrease in the near future. The company expects its cash used in operating activities to increase in the next 12 months.

Management Comments

Management is developing plans to achieve profitability.
Management believes that the company's current office space is adequate for its current and immediately foreseeable operating needs.
Management recognizes that there are inherent limitations in the effectiveness of any internal control over financial reporting, including the possibility of human error and the circumvention or overriding of internal control.

Industry Context

The healthcare industry is highly regulated and subject to changing political, legislative, regulatory, and other influences. The company faces intense competition from larger healthcare providers with greater resources.

Comparison to Industry Standards

The document does not provide specific comparisons to industry standards or comparable companies.
The document does not provide specific details about competitors' projects or results.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Bylaws Amendment	The Board approved and adopted an amendment to the company's Amended and Restated Bylaws. The Amendment reduces the quorum at any meeting of stockholders to one-third of the voting power of the shares of capital stock outstanding and entitled to vote at the meeting.	March 7, 2025	The Amendment reduces the quorum at any meeting of stockholders, which may make it easier to conduct business at stockholder meetings.

Legal Proceedings

The Company, Genexosome and the Research Institute entered into a settlement agreement dated June 7, 2022 (the Settlement Agreement), whereby the Company agreed to pay the Research Institute $450,000 on each of the sixty-day, one year and two-year anniversaries of the Settlement Date.

Related Party Transactions

The company leases space of its commercial real property located in New Jersey to D.P. Capital Investments LLC, which is controlled by Wenzhao Lu, the company's chairman of the Board of Directors.
From time to time, Wilbert Tauzin, a director of the company, and his son provide consulting services to the company.
Lab Services MSO paid shared expense on behalf of the company.
The company entered into a Membership Interest Purchase Agreement with Mr. Lu, the company's chairman of the Board of Directors, pursuant to which Mr. Lu will acquire from the company 30% of the total outstanding membership interests of Avalon RT 9.

Stakeholder Impact

Shareholders may experience dilution of their ownership interests due to future issuances of additional shares of common or preferred stock.
Employees may be affected by the company's cost-cutting measures and strategic shifts.
Customers may be affected by the company's focus on precision diagnostic consumer products.
The company's creditors may be affected by its ability to repay its debt obligations.

Next Steps

The company will seek approval of its stockholders to approve the issuance of shares of common stock to be issued to YOOV shareholders in connection with the Merger.
The company will seek approval of its stockholders to amend the company's certificate of incorporation to effect a reverse stock split of the company's common stock to the extent the Company and YOOV mutually agree implementing such reverse stock split is necessary to meet Nasdaq's listing requirements.
The company will continue to seek additional capital through equity and debt offerings.

Key Dates

Date	Description
December 18, 2020	The Holding Foreign Companies Accountable Act (HFCA Act) was enacted.
February 2023	The company acquired a 40% membership interest in Lab Services MSO.
June 2023	The company entered into a sales agreement with Roth Capital Partners, LLC.
July 1, 2023	Start date for sales of common stock pursuant to the Sales Agreement with Roth.
October 23, 2024	The company filed a certificate of amendment to effectuate a reverse stock split.
October 25, 2024	The amendment to effectuate a reverse stock split became effective.
October 28, 2024	The company effectuated a reverse stock split of the company's common stock at a ratio of 1-for-15.
December 13, 2024	The company filed a certificate of designations of preferences, rights, and limitations of Series C Convertible Preferred Stock.
December 19, 2024	The company entered into a securities purchase agreement with York Sun Investment Holding Limited for the issuance of Series C Convertible Preferred Stock.
December 24, 2024	The first closing occurred with respect to the Investor's purchase of 3,500 shares of Series C Convertible Preferred Stock in exchange for $3,500,000.
January 6, 2025	The company filed a certificate of designations of preferences, rights, and limitations of Series D Convertible Preferred Stock.
January 9, 2025	The company entered into an exchange agreement with Wenzhao Lu, exchanging Series A Preferred Stock for Series D Preferred Stock.
February 26, 2025	The company entered into a Redemption and Abandonment Agreement with Lab Services MSO, redeeming the 40% equity interest in Lab Services MSO.
March 7, 2025	The company entered into an Agreement and Plan of Merger with YOOV Group Holding Limited.
March 7, 2025	The company filed a Certificate of Elimination relating to each of the Series A Preferred Stock and the Series B Preferred Stock.
March 7, 2025	The Board approved and adopted an amendment to the company's Amended and Restated Bylaws.
March 31, 2025	Date of outstanding shares of common stock.
Third quarter 2025	Expected completion of the merger with YOOV Group Holding Limited.
March 7, 2026	End Date for the Merger Agreement, subject to extension.

Keywords

Merger, KetoAir, Convertible Preferred Stock, Reverse Stock Split, Going Concern, Financial Results, Diagnostic Products, Avalon GloboCare

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.